

BELLICUM PHARMACEUTICALS, INC  
Form DEFA14A  
April 27, 2016

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. )

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

BELLICUM PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

☒ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Title of each class of securities to which transaction applies:

1.

Aggregate number of securities to which transaction applies:

2.

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

3.

Proposed maximum aggregate value of transaction:

4.

Total fee paid:

5.

☐ Fee paid previously with preliminary materials.

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form DEFA14A

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:

6.

Form, Schedule or Registration Statement No.:

7.

Filing Party:

8.

Date Filed:

9.

---

\*\*\* Exercise Your Right to Vote \*\*\*

Important Notice Regarding the Availability of Proxy Materials for the  
Stockholder Meeting to Be Held on June 15, 2016.

BELLICUM PHARMACEUTICALS, INC. Meeting Information  
Type: Annual Meeting  
For  
holders as April 18, 2016  
of:  
Date: June 15, 2016  
Time: 10:00 AM CDT  
Bellicum  
Location: Pharmaceuticals,  
Inc.  
Meeting Room,  
8th Floor  
2130 West  
Holcombe Blvd.  
Houston, TX  
77030

BELLICUM PHARMACEUTICALS, INC.  
2130 W. HOLCOMBE BLVD., STE. 800  
HOUSTON, TX 77030

You are receiving this  
communication because  
you hold shares of the  
company named above.  
This is not a ballot. You  
cannot use this notice to  
vote these shares. This  
communication presents  
only an overview of the  
more complete proxy  
materials that are available  
to you on the Internet or by  
mail. You may view the  
proxy materials online at  
[www.proxyvote.com](http://www.proxyvote.com) or  
easily request a paper copy  
(see reverse side).

We encourage you to  
access and review all of the  
important information  
contained in the proxy  
materials before voting.

See the reverse side of this  
notice to obtain proxy

materials and voting  
instructions.

---

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

PROXY STATEMENT

FORM 10-K

How to View Online:

Have the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX (located on the following page) and visit: [www.proxyvote.com](http://www.proxyvote.com).

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

- 1) BY INTERNET: [www.proxyvote.com](http://www.proxyvote.com)
- 2) TELEPHONE: 1-800-579-1639
- 3) BY E-MAIL\*: [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com)

\* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 1, 2016 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

**Vote In Person:** Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

**Vote By Internet:** To vote now by Internet, go to [www.proxyvote.com](http://www.proxyvote.com). Have the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX (located on the following page) available and follow the instructions.

**Vote By Mail:** You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

---

Voting  
Items  
Your  
Board of  
Directors  
recommends  
you vote  
FOR all  
nominees  
for  
director  
listed  
below:

1 Election of directors

Nominees:

01)

James

F.

Brown

02)

Kevin

M.

Slawin,

M.D.

Your Board of Directors  
recommends you vote  
FOR the following  
proposal:

Ratification of the  
selection of ERNST  
& YOUNG LLP as  
independent

2. registered public  
accounting firm of  
the Company for its  
fiscal year ending  
December 31, 2016.

NOTE: In their best  
judgment, the proxies  
are authorized to vote  
upon such other  
business as may  
properly come before  
the Annual Meeting.  
This proxy when

properly executed will  
be voted as directed  
herein by the  
undersigned  
stockholder. If no  
direction is made, this  
proxy will be voted  
FOR ALL NOMINEES  
in Proposal 1 and FOR  
Proposal 2.